Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study

• Prif Awduron: Tiina Levälampi (Awdur), Johanna Kärki (Awdur), Katariina Rebane (Awdur), Paula Vähäsalo (Awdur), Merja Malin (Awdur), Liisa Kröger (Awdur), Minna-Maija Grönlund (Awdur), Maria Backström (Awdur), Heini Pohjankoski (Awdur), Hannu Kautiainen (Awdur), Sakari Jokiranta (Awdur), Kristiina Aalto (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: BMC, 2023-03-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Abstract Background Etanercept (ETN) is widely used tumour necrosis factor (TNF) blocker in the treatment of juvenile idiopathic arthritis (JIA) when traditional synthetic disease modifying antirheumatic drug (sDMARD) therapy is not sufficient. There is limited information about the effects of metho...